Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients.
Idiopathic pulmonary fibrosis
Immunology
Mesenchymal stem cells
Therapy
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
31 01 2022
31 01 2022
Historique:
received:
03
06
2021
accepted:
21
12
2021
entrez:
1
2
2022
pubmed:
2
2
2022
medline:
24
3
2022
Statut:
epublish
Résumé
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive pulmonary disease characterized by aberrant tissue remodeling, formation of scar tissue within the lungs and continuous loss of lung function. The areas of fibrosis seen in lungs of IPF patients share many features with normal aging lung including cellular senescence. The contribution of the immune system to the etiology of IPF remains poorly understood. Evidence obtained from animal models and human studies suggests that innate and adaptive immune processes can orchestrate existing fibrotic responses. Currently, there is only modest effective pharmacotherapy for IPF. Mesenchymal stem cells (MSCs)-based therapies have emerged as a potential option treatment of IPF. This study characterizes the functionality of autologous MSCs for use as an IPF therapy and presents an attempt to determine whether the disease occurring in the lungs is associated with an alterated immune system. Comprehensive characterization of autologous adipose-derived MSCs (aMSCs) from 5 IPF patient and 5 age- and gender-matched healthy controls (HC) was done using flow cytometry, PCR (ddPCR), multiplex Luminex xMAP technology, confocal microscopy self-renewal capacity and osteogenic differentiation. Additionally, multi-parameter quantitative flow cytometry of unmanipulated whole blood of 15 IPF patients and 87 (30 age- and gender-matched) HC was used to analyze 110 peripheral phenotypes to determine disease-associated changes in the immune system. There are no differences between autologous aMSCs from IPF patients and HC in their stem cell properties, self-renewal capacity, osteogenic differentiation, secretome content, cell cycle inhibitor marker levels and mitochondrial health. IPF patients had altered peripheral blood immunophenotype including reduced B cells subsets, increased T cell subsets and increased granulocytes demonstrating disease-associated alterations in the immune system. Our results indicate that there are no differences in aMSC properties from IPF patients and HC, suggesting that autologous aMSCs may be an acceptable option for IPF therapy. The altered immune system of IPF patients may be a valuable biomarker for disease burden and monitoring therapeutic response.
Sections du résumé
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive pulmonary disease characterized by aberrant tissue remodeling, formation of scar tissue within the lungs and continuous loss of lung function. The areas of fibrosis seen in lungs of IPF patients share many features with normal aging lung including cellular senescence. The contribution of the immune system to the etiology of IPF remains poorly understood. Evidence obtained from animal models and human studies suggests that innate and adaptive immune processes can orchestrate existing fibrotic responses. Currently, there is only modest effective pharmacotherapy for IPF. Mesenchymal stem cells (MSCs)-based therapies have emerged as a potential option treatment of IPF. This study characterizes the functionality of autologous MSCs for use as an IPF therapy and presents an attempt to determine whether the disease occurring in the lungs is associated with an alterated immune system.
METHODS
Comprehensive characterization of autologous adipose-derived MSCs (aMSCs) from 5 IPF patient and 5 age- and gender-matched healthy controls (HC) was done using flow cytometry, PCR (ddPCR), multiplex Luminex xMAP technology, confocal microscopy self-renewal capacity and osteogenic differentiation. Additionally, multi-parameter quantitative flow cytometry of unmanipulated whole blood of 15 IPF patients and 87 (30 age- and gender-matched) HC was used to analyze 110 peripheral phenotypes to determine disease-associated changes in the immune system.
RESULTS
There are no differences between autologous aMSCs from IPF patients and HC in their stem cell properties, self-renewal capacity, osteogenic differentiation, secretome content, cell cycle inhibitor marker levels and mitochondrial health. IPF patients had altered peripheral blood immunophenotype including reduced B cells subsets, increased T cell subsets and increased granulocytes demonstrating disease-associated alterations in the immune system.
CONCLUSIONS
Our results indicate that there are no differences in aMSC properties from IPF patients and HC, suggesting that autologous aMSCs may be an acceptable option for IPF therapy. The altered immune system of IPF patients may be a valuable biomarker for disease burden and monitoring therapeutic response.
Identifiants
pubmed: 35101101
doi: 10.1186/s13287-021-02692-0
pii: 10.1186/s13287-021-02692-0
pmc: PMC8802496
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
45Informations de copyright
© 2022. The Author(s).
Références
Int Immunopharmacol. 2013 Dec;17(4):1185-97
pubmed: 24263067
Am J Respir Crit Care Med. 2009 Jun 15;179(12):1121-30
pubmed: 19342412
J Immunother Cancer. 2017 Apr 18;5:30
pubmed: 28428879
Gastroenterology. 2017 Jul;153(1):59-62.e2
pubmed: 28400193
Pulm Med. 2019 Nov 20;2019:1907807
pubmed: 31827925
J Leukoc Biol. 2015 Aug;98(2):143-52
pubmed: 25743626
Mech Ageing Dev. 2009 Oct;130(10):681-90
pubmed: 19698733
Thorax. 2015 Jan;70(1):48-56
pubmed: 25217476
Am J Respir Crit Care Med. 2014 Apr 15;189(8):966-74
pubmed: 24628285
Am J Respir Cell Mol Biol. 2016 Sep;55(3):309-22
pubmed: 27149613
Lancet. 2012 Aug 18;380(9842):680-8
pubmed: 22901889
J Inflamm (Lond). 2007 Jun 19;4:14
pubmed: 17578573
Stem Cells Transl Med. 2020 Jan;9(1):6-16
pubmed: 31613055
J Clin Med. 2019 Jun 26;8(7):
pubmed: 31247996
PLoS One. 2015 Mar 23;10(3):e0121546
pubmed: 25799053
Front Med (Lausanne). 2018 May 15;5:142
pubmed: 29868594
Blood. 1992 Jun 15;79(12):3239-44
pubmed: 1375847
J Immunother Cancer. 2013 Jun 27;1:7
pubmed: 25512872
Dis Colon Rectum. 2019 May;62(5):615-622
pubmed: 30664554
J Clin Med. 2016 Dec 26;6(1):
pubmed: 28035951
Mod Pathol. 2012 Mar;25(3):416-33
pubmed: 22037258
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):655-9
pubmed: 8118632
J Inflamm Res. 2013;6:63-70
pubmed: 23576879
Cytokine. 2014 Apr;66(2):119-26
pubmed: 24418172
Clin Chem. 2018 Dec;64(12):1732-1742
pubmed: 30237149
Chest. 2017 May;151(5):971-981
pubmed: 27890713
Chest. 2008 Jan;133(1):226-32
pubmed: 18071016
Thorax. 1999 Nov;54(11):1015-20
pubmed: 10525561
J Transl Med. 2015 Jan 27;13:19
pubmed: 25622723
PLoS One. 2010 Jan 29;5(1):e8959
pubmed: 20126467
Stem Cells Dev. 2015 Sep 1;24(17):1957-71
pubmed: 26134242
J Allergy Clin Immunol. 2005 Feb;115(2):412-7
pubmed: 15696104
Int J Mol Sci. 2018 Dec 05;19(12):
pubmed: 30563106
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Mucosal Immunol. 2019 Jan;12(1):212-222
pubmed: 30315241
J Transl Med. 2013 Jul 15;11:171
pubmed: 23855653
PLoS One. 2017 Jul 25;12(7):e0182002
pubmed: 28742871
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8407-11
pubmed: 12815096
Front Med (Lausanne). 2018 Mar 20;5:43
pubmed: 29616220
Chest. 2017 May;151(5):951-952
pubmed: 28483127
Respirology. 2014 Oct;19(7):1013-8
pubmed: 25039426
Respir Res. 2019 Oct 24;20(1):232
pubmed: 31651327
Neurology. 2019 Jul 2;93(1):e77-e87
pubmed: 31152011
Cells. 2012 Dec;1(4):874
pubmed: 23626909
Lancet Respir Med. 2019 Jun;7(6):497-508
pubmed: 30935881
Exp Gerontol. 2020 Apr;132:110836
pubmed: 31958492
Front Immunol. 2016 Nov 23;7:516
pubmed: 27933058
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Mol Pharm. 2013 Jan 7;10(1):77-89
pubmed: 23215004
Immunol Lett. 2014 Nov;162(1 Pt B):303-9
pubmed: 24951896
Sci Rep. 2017 May 25;7(1):2409
pubmed: 28546538
Biomol Detect Quantif. 2017 Sep 20;13:40-48
pubmed: 29021971
Mayo Clin Proc. 2014 Aug;89(8):1130-42
pubmed: 24867394
Am J Physiol Cell Physiol. 2007 Jan;292(1):C157-63
pubmed: 16870828
Respir Res. 2017 Sep 8;18(1):170
pubmed: 28886713
J Clin Invest. 2021 Jan 19;131(2):
pubmed: 33463535
Int J Immunopathol Pharmacol. 2005 Jul-Sep;18(3):541-5
pubmed: 16164835
N Engl J Med. 2012 May 24;366(21):1968-77
pubmed: 22607134
Respir Res. 2019 Nov 6;20(1):244
pubmed: 31694639
Chest. 1997 Nov 5;112(5):1338-43
pubmed: 9367478
J Immunol. 2013 Sep 1;191(5):2089-95
pubmed: 23872052
Sci Rep. 2017 Apr 25;7:46560
pubmed: 28440314
Stem Cell Res Ther. 2016 Aug 11;7(1):107
pubmed: 27515308
J Am Soc Nephrol. 2017 Sep;28(9):2777-2785
pubmed: 28461553
J Immunol. 2007 Aug 15;179(4):2592-9
pubmed: 17675522
Lancet. 2009 Jul 18;374(9685):222-8
pubmed: 19570573
Nat Rev Immunol. 2008 Sep;8(9):726-36
pubmed: 19172693
Cell Transplant. 2011;20(6):797-811
pubmed: 21092406
Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7841-5
pubmed: 11427725
J Cell Biochem. 2014 Oct;115(10):1816-28
pubmed: 24905804
Mayo Clin Proc. 2020 Feb;95(2):406-414
pubmed: 31785831
Am J Respir Crit Care Med. 2008 Nov 1;178(9):948-55
pubmed: 18669816